Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke.
about
Epigenetic Regulation of Oxidative Stress in Ischemic StrokeHistone Deacetylases Exert Class-Specific Roles in Conditioning the Brain and Heart Against Acute Ischemic InjuryTransglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS blockThe interplay between microRNAs and histone deacetylases in neurological diseasesTargeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular diseaseHistone methylation patterns in astrocytes are influenced by age following ischemiaHDAC6 is a target for protection and regeneration following injury in the nervous systemGenome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.Epigenetics: an expanding new piece of the stroke puzzlePromoting axonal rewiring to improve outcome after strokeEvidence HDAC9 genetic variant associated with ischemic stroke increases risk via promoting carotid atherosclerosis.Comprehensive gene expression profiling reveals synergistic functional networks in cerebral vessels after hypertension or hypercholesterolemia.Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia.A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation.Class IIa histone deacetylases affect neuronal remodeling and functional outcome after strokeHypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia.Inhibition of histone methyltransferases SUV39H1 and G9a leads to neuroprotection in an in vitro model of cerebral ischemia.Epigenetic Regulation of Tissue-Type Plasminogen Activator in Human Brain Tissue and Brain-Derived CellsEmerging role of epigenetics in stroke: part 1: DNA methylation and chromatin modifications.HDAC9 exacerbates endothelial injury in cerebral ischaemia/reperfusion injurySynergy of homocysteine, microRNA, and epigenetics: a novel therapeutic approach for stroke.Epigenetic mechanisms in cerebral ischemia.Chromatin-modifying agents for epigenetic reprogramming and endogenous neural stem cell-mediated repair in stroke.Chromatin modifications associated with DNA double-strand breaks repair as potential targets for neurological diseases.Inhibition of Histone Deacetylase 3 (HDAC3) Mediates Ischemic Preconditioning and Protects Cortical Neurons against Ischemia in RatsHDAC inhibitors and neurodegeneration: at the edge between protection and damage.Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies.Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.The epigenetics of stroke recovery and rehabilitation: from polycomb to histone deacetylases.Mechanisms and treatment of ischaemic stroke--insights from genetic associations.The Emerging Role of Epigenetics in Cerebral Ischemia.Sodium Butyrate, a Histone Deacetylase Inhibitor, Exhibits Neuroprotective/Neurogenic Effects in a Rat Model of Neonatal Hypoxia-Ischemia.Histone deacetylase inhibitors preserve white matter structure and function during ischemia by conserving ATP and reducing excitotoxicity.LIM domain only 4 protein promotes granulocyte colony-stimulating factor-induced signaling in neurons.Epigenetics and the nervous system: epiphenomenon or missing piece of the neurotherapeutic puzzle?Inhibiting Histone Deacetylase 2 (HDAC2) Promotes Functional Recovery From Stroke.Sex differences in the brain: Implications for behavioral and biomedical research.New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death.MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.
P2860
Q26743597-1014BA9E-3EC8-43A0-B567-A622B7456054Q26801660-00352E74-1AFB-48E2-8FFE-EB943818CAD6Q26824549-77EAE13D-3749-4488-990E-E1981C0C4F3FQ27024466-DE3DD223-1C94-4797-B147-392C43002980Q28085588-0CE14539-3FA3-4A26-A19A-FDB7DEE8E89DQ28392267-FA8E1CA6-E896-461E-8200-792D5984EA82Q28575078-9E80AB1B-0315-4860-926A-08C21A9C948EQ29417129-4D48795E-BAA1-45CB-AEC8-603ACED06300Q33352309-F3E3D2B6-7B3D-4EBB-9B95-72D1296993FAQ34020263-171D71CC-0603-492E-9730-56E46082F00CQ34390824-B2F02E70-5DB9-4AC9-B76C-4303C489A2A6Q34848063-8A1AC762-2AD0-4FED-B59B-8B353DC55F2AQ35237734-E1691DFC-0681-499B-9701-9535D38C201CQ35867650-BB7F627A-3A82-44DF-A95B-488D235196DFQ35996642-DD9622AF-3FE5-4B30-BC8E-5CB377AE429EQ36079321-1B446E7B-36FF-4D92-8E9F-BCA45F77D3E9Q36185344-1D3C8CBC-7A44-48EF-AA84-CD8689D0B77FQ36267373-404F0285-404A-4FDA-B971-6104A1FD8962Q36504031-D080EB5E-46C3-4297-8DF4-F0439ED6ED80Q36938455-05141B9A-8C31-421F-8EB9-2743565DDFC6Q36942370-C8310428-14E8-471F-B6AD-3EA7910A81F7Q36961798-DE123A48-0D6F-4E27-A992-49CD43DAE064Q37150340-22B75D67-81C2-47A9-A4C0-0666A0FEFDDCQ37151715-B9D4ECA3-B63B-4517-A430-66FC542E0E83Q37249162-92030667-2DE4-4BBE-8926-5C4A35C7AF47Q37443800-38FCFAB5-91D7-4B98-904C-DA50E8EDD68AQ37685428-3F57912B-5D5C-4F1F-A27B-32157D03866EQ37787304-D6CED8AB-C0F3-4234-8116-C3DB46324F2EQ37832963-82400A07-4E2F-4F86-91A5-7EF7C622FC92Q38149089-356EC224-FD95-49B0-851D-9F0040F97594Q38263023-48E1A2A3-410A-4639-BD5C-95F95BA6426AQ38740709-4F240426-5D98-4195-A39E-92FE88592BECQ38826149-2D9CC742-2564-4692-8987-6A93D1046BD0Q41763185-AE40FD5A-DDFB-41BF-887A-10858434061FQ42053383-9C2ED316-D7C7-485A-9A31-06315F8C47CCQ43138935-939BA997-89B2-43F7-8460-A3CD16CE6F86Q47156058-48A9E2EF-C558-4485-BA9E-F745AA527574Q47276687-9FDE5085-1EA8-4EEB-83A3-80FD88CEF4A8Q48181021-63CA5502-A634-49D0-BDF7-CA4B08E7C4C6Q48919917-1E406076-05DA-45D9-AB6A-CA67BA0FE34D
P2860
Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting histone deacetylases ...... he diverse outcomes of stroke.
@en
Targeting histone deacetylases ...... he diverse outcomes of stroke.
@nl
type
label
Targeting histone deacetylases ...... he diverse outcomes of stroke.
@en
Targeting histone deacetylases ...... he diverse outcomes of stroke.
@nl
prefLabel
Targeting histone deacetylases ...... he diverse outcomes of stroke.
@en
Targeting histone deacetylases ...... he diverse outcomes of stroke.
@nl
P2093
P1433
P1476
Targeting histone deacetylases ...... he diverse outcomes of stroke.
@en
P2093
Brett Langley
Camille Brochier
Mark A Rivieccio
P304
P356
10.1161/STROKEAHA.108.540229
P407
P577
2009-05-28T00:00:00Z